Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients.
10.3346/jkms.2015.30.3.290
- Author:
Jee Hyun KIM
1
;
Seul Ki KIM
;
Hee Jun LEE
;
Jung Ryeol LEE
;
Byung Chul JEE
;
Chang Suk SUH
;
Seok Hyun KIM
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea. leejrmd@snu.ac.kr
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Controlled Ovarian Stimulation;
Random-start;
Fertility Preservation;
Emergency;
Cancer;
In Vitro Fertilization Outcomes
- MeSH:
Cryopreservation;
Estradiol/blood;
Female;
Fertility Preservation/*methods;
Fertilization in Vitro;
Humans;
Infertility, Female/surgery;
Neoplasms;
Nitriles/therapeutic use;
Oocyte Retrieval/*methods;
Ovulation Induction/*methods;
Retrospective Studies;
Triazoles/therapeutic use
- From:Journal of Korean Medical Science
2015;30(3):290-295
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study aimed to evaluate the efficacy of random-start controlled ovarian stimulation (COS) in cancer patients for emergency fertility preservation. In this retrospective comparative study, 22 patients diagnosed with cancer and 44 infertile women undergoing conventional in vitro fertilization (IVF) were included. In cancer patients, ovarian stimulation was started on the day of referral, irrespective of their menstrual cycle date. The control group was selected by age matching among women undergoing conventional IVF. COS outcomes were compared between groups. The number of total and mature oocytes retrieved and the oocyte maturity rate were higher in the random-start group than in the conventional-start group. However, duration of ovarian stimulation was longer in the random-start group (11.4 vs. 10.3 days, P = 0.004). The addition of letrozole to lower the estradiol level during COS did not adversely affect total oocytes retrieved. However, oocyte maturity rate was lower in cycles with letrozole than in cycles without letrozole (71.6% vs. 58.2%, P = 0.019). Our study confirms the feasibility and effectiveness of random-start COS in cancer patients.
